Greater Than Minimal Risk, No Direct Benefit – Bridging Drug Trials and Novel Therapy in Pediatric Populations

, &
American Journal of Bioethics 20 (4):102-103 (2020)
  Copy   BIBTEX

Abstract

Volume 20, Issue 4, May 2020, Page 102-103.

Categories

Keywords

Reprint years

DOI

10.1080/15265161.2020.1730488

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,164

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Clearing Muddy Waters: The Need to Reconceptualize Minor Increase over Minimal Risk in Pediatric Rare Disease Research.Devan M. Duenas, Benjamin S. Wilfond & Liza-Marie Johnson - 2020 - American Journal of Bioethics 20 (4):8-10.
When ethics constrains clinical research: trial design of control arms in "greater than minimal risk" pediatric trials.Inmaculada de Melo-Martin - 2011 - Human Gene Therapy 22 (9):1121-27.
Defining the Boundaries of a Right to Adequate Protection: A New Lens on Pediatric Research Ethics.David DeGrazia, Michelle Groman & Lisa M. Lee - 2017 - Journal of Medicine and Philosophy 42 (2):132-153.
Acceptable risks and burdens for children in research without direct benefit: a systematic analysis of the decisions made by the Dutch Central Committee.A. E. Westra, R. N. Sukhai, J. M. Wit, I. D. de Beaufort & A. F. Cohen - 2010 - Journal of Medical Ethics 36 (7):420-424.
The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials.Spencer Phillips Hey & Jonathan Kimmelman - 2014 - Kennedy Institute of Ethics Journal 24 (2):121-139.
Pediatric Magnetic Resonance Research and the Minimal-Risk Standard.Matthias Schmidt, Jennifer Marshall, Jocelyn Downie & Michael Hadskis - 2011 - IRB: Ethics & Human Research 33 (5):1-6.
Why Even Inappropriate Parental Consent Might Be Enough to Justify Minimal Risk Pediatric Research Without Clinical Benefit.David Hunter - 2012 - American Journal of Bioethics 12 (1):35 - 36.
Using the Minimal Risk Threshold for All “No-Benefit” Pediatric Studies.Loretta M. Kopelman - 2014 - American Journal of Bioethics 14 (9):17-18.
Rethinking Risk in Pediatric Research.Kathleen Cranley Glass & Ariella Binik - 2008 - Journal of Law, Medicine and Ethics 36 (3):567-576.
A call to restructure the drug development process: Government over-regulation and non-innovative late stage (phase III) clinical trials are major obstacles to advances in health care.Thomas C. Jones - 2005 - Science and Engineering Ethics 11 (4):575-587.
Bringing Known Drugs to Pediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal Risk.Akshay Sharma & Liza-Marie Johnson - 2020 - American Journal of Bioethics 20 (4):106-108.
Just a Spoonful of Sugar: Drug Safety for Pediatric Populations.Barbara A. Noah - 2009 - Journal of Law, Medicine and Ethics 37 (2):280-291.
Minimal risk revisited: the ethics of clinical research with children.Ariella Binik - unknown
Balancing Scientific Progress With Pediatric Protections: No Direct Benefit Now, But Potential Novel Therapy in the Future.Susannah W. Lee & Jessica C. Ginsberg - 2020 - American Journal of Bioethics 20 (4):108-110.
A Defense of The-Risks-of-Daily-Life.Ariella Binik - 2017 - Kennedy Institute of Ethics Journal 27 (3):413-442.

Analytics

Added to PP
2020-03-25

Downloads
9 (#1,181,695)

6 months
6 (#417,196)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Citations of this work

Add more citations

References found in this work

No references found.

Add more references